

## Review Article

Indian J Med Res 134, September 2011, pp 261-269

# Umbilical cord blood: Current status & promise for the future

David McKenna & Jayesh Sheth\*

*Molecular & Cellular Therapeutics, University of Minnesota, Minneapolis, MN, USA  
& \*Foundation for Research in Genetics & Endocrinology, Ahmedabad, India*

Received April 15, 2010

**Umbilical cord blood (UCB) has been shown to be a suitable source of haematopoietic stem cells (HSCs) for haematopoietic reconstitution. An increase in the number of UCB transplants indicates an expansion of utility in a broad spectrum of disease conditions. Along with the advantages, UCB also has limitations, and hence several investigators are working to further optimize UCB for this use. Beyond haematopoietic transplantation, additional potential applications of UCB include immunotherapy, tissue engineering and regenerative medicine. UCB banking has improved with time largely due to involvement of professional organizations and their published standards. However, accreditation of these organizations remains voluntary, and in India three of ten banks are public with the remaining being private. Only one public and one private bank are American Association of Blood Banks (AABB) accredited in India. Government agencies need to provide regulatory and safety oversight, which is lacking in several countries. Public policy regarding UCB is in its infancy throughout most of the world. Ethical issues, including access to UCB banking and use as therapy for diseases other than haematological and metabolic disorders are in the early phase of trials and remain speculative.**

**Key words** Haematopoietic reconstitution - stem cells - umbilical cord blood (UCB)

### Introduction

Stem cell based therapies are increasingly being utilized with promising results in both malignant and non-malignant disorders<sup>1-3</sup>. Three sources of cells have been used for haematopoietic reconstitution – bone marrow (BM), peripheral blood (PB), and umbilical cord blood (UCB)<sup>3-5</sup>. UCB, the most recently identified source of stem cells, appears to be as effective as bone marrow when an HLA-matched adult donor is not available<sup>6,7</sup>. In the past decade, the clinical applications of UCB-based cell therapies have broadened with a growing number of diseases treated with haematopoietic stem cell (HSC) transplantation. Additionally, several

investigational human trials involving cell types derived from UCB have been initiated<sup>4,6,7</sup>.

As the clinical utility has become apparent, collection and banking of UCB have become more widespread all over the world<sup>8</sup>. The expansion of UCB banking has led to the establishment of UCB quality standards by professional groups such as AABB (formerly known as American Association of Blood Banks) and the Foundation for Accreditation of Cellular Therapy (FACT)/NETCORD<sup>9,10</sup>. These best-practice expectations pertain to collection, testing, processing and banking of UCB for transplantation<sup>11</sup>. There are at least 142 public [three in India – Relicord (Reliance Life

Science), (Jeevan Cord and Stemcyte) and 25 private (seven in India) UCB banks worldwide<sup>12,13</sup> with several more likely to open in the near future. While standards appropriately cover UCB banking, guidelines regarding other issues including those with ethical implications (e.g., patient access, clinical applications) are lacking in particular for autologous UCB transplantation. In India and other countries private UCB banking dominates, limiting general public access to promising therapies. Further, worldwide, clinical trials for a variety of diseases are ongoing despite inadequate pre-clinical studies and regulatory/safety oversight.

### The success of UCB transplantation in the world

While bone marrow and peripheral blood stem cell transplants have a proven track record of success, the search process can take several months. Despite almost 13 million registered volunteer donors are presently accessible worldwide, many patients do not get HLA matched grafts. Hence, the applicability of HSC transplantation has markedly expanded with the introduction of UCB, especially for ethnic and racial minorities. Therefore, UCB has gained popularity and acceptability as an alternative transplant source for patients lacking appropriate adult donors. In a report of 623 consecutive patients undergoing myeloablative transplant at the University of Minnesota, Tomblyn and colleagues<sup>14</sup> have shown that ALL (acute lymphoblastic leukemia) patient lacking a sibling donor can seek UCB or a well-matched unrelated donor and have equivalent long-term survival. After a median of 8.3 years of follow up, five year overall survival, leukemia free survival (LFS) and relapse were 29, 26 and 43 per cent respectively. Five year LFS was 40, 42 and 49 per cent with related donors (RD), well matched unrelated donors (URD) and UCB sources, respectively, while relapse was 31, 17 and 27 per cent in the same group. Several additional studies support satisfactory results of UCB transplant as compared to other sources of haematopoietic stem cells<sup>15,16</sup>. In addition to paediatric and adult haematological malignancies, UCB has potential applications in non-malignant and metabolic disorders<sup>17</sup>. Due to the decreased risk of graft versus host diseases (GVHD) the use of UCB transplant over related BMT in thalassaemia<sup>18,19</sup>. In cases of Fanconi anemia, Gluckman *et al*<sup>20</sup> have demonstrated significantly improved engraftment (89 vs 69%) and survival (52 vs. 13%) in those received fludarabine versus no fludarabine.

In metabolic storage disorders the only therapeutic option is enzyme replacement therapy which is

expensive with a long-term requirement. Hence, UCB transplant is desirable and a promising alternative therapeutic option with long term benefits. Prasad *et al*<sup>21</sup> have reported results of 159 paediatric patients with inherited metabolic disorders who received UCB transplant. Engraftment occurred in 87.1 per cent and one year overall survival was 71.8 per cent. Notably those children with high performance status had better overall survival of nearly 85 per cent which emphasizes the importance of UCB transplant early in the course of the disease.

Most UCB banks in India have been opened in the last few years, and UCB transplantation is in its infancy, very few reports are available for application to acquired and constitutional haematological disorders and none for metabolic disorders. Till date approximately 32 patients have been transplanted using related or unrelated UCB. Of these 2 patients of relapsed leukemia were transplanted using mismatched sibling cord [UCB processed at Life cell and Cryo Bank] and one died of disease relapse and other of sepsis. One child was transplanted using fresh fully matched cord and the child is well 12 years on and did not go through any cord bank. In 15 patients mainly for relapsed leukemia and aplastic anemia unrelated cord blood was used with TRM of 55 per cent at Apollo, Chennai. While one patient of leukemia transplanted at Gujarat Cancer & Research Institute (GCRI), Ahmedabad expired due to disease related mortality after transplantation. The high mortality rate appears to be due to selection of high risk cases under this group (personal communication with Dr Revathi Raj, Chennai and Dr Sandip Shah, Ahmedabad).

To date, around 13 cases of thalassaemia have been treated using UCB transplantation. Of these, six cases were transplanted using fully matched sibling UCB at Apollo hospitals, Chennai. UCB units were obtained from Life Cell and Cord bank. Thalassaemia free survival was 83 per cent and all patients had additional bone marrow from siblings as there was inadequate cell dose in cord blood (personal communication with Dr Revathi Raj, Chennai). Similarly, seven unrelated UCB units were utilized to treat thalassaemia cases at GCRI, Ahmedabad. The unrelated UCB units were procured from Relicord and Stemcyte UCB banks. TRM was 0 per cent at both the centers. At GCRI, Ahmedabad, two thalassaemia patients had disease free survival after 2 years and 1 year of transplantation, and one remained hospitalized post-transplantation. Failure of engraftment was observed in four cases which is

likely to be due to low number of total nucleated cell (TNC) ( $2-3 \times 10^7$ ) used in transplantation (personal communication from Dr Sandip Shah, Ahmedabad). Considering large number of thalassaemia patients born in the country; these transplantations are comparatively very less mainly because of cost prohibition, lack of sufficient UCB depository and because public UCB banks are in early stage of development. In the coming years with an increased transplantation using UCB as a source of haematopoietic stem cells, more experience will undoubtedly be gained<sup>22</sup>.

### Difference between related and unrelated transplants

The vast majority of UCB transplants are from unrelated donors. Despite the fact that related UCB transplant was largely replaced by unrelated donor transplant, the former source of stem cells still remains a reality in a minority with not having access to suitable donors<sup>23</sup>. In this era of public and private UCB banking for storing and freezing UCB units, related UCB transplant may regain priority. The EUROCORD group reported the results of related UCB transplant in 44 children with haemoglobinopathies (thalassaemia in 33 and sickle cell anaemia in 11) who received fully matched UCB grafts with only 3 children receiving 1 locus mismatched grafts<sup>18</sup>. In their series donor type reconstitution of hematopoiesis was obtained in 86.4 per cent of transplants with median times to neutrophil and platelet engraftments at 23 and 39 days, respectively with overall disease free survival of 79 and 90 per cent in thalassaemia and sickle cell anaemia respectively. GVHD was limited in 2 of 36 patients with no transplant related mortality receiving related UCB transplantation.

In recent years with growing demand of transplantation, unrelated UCBT (UD-UCBT) has become an alternative transplant method for patients lacking a suitable donor. In a study nine autologous and 41 allogenic transplants were carried out using privately banked UCB<sup>24</sup>. The study demonstrated that 36 of 41 allogenic cases were due to known indication of haematological malignancy while those with autologous mainly included neuroblastoma, retinoblastoma, Shwachman Diamond syndrome, brain tumour and severe aplastic anaemia. The study indicates that very few would choose autologous UCB over alternative stem cell source for ALL in second remission. In contrast, 55 per cent would choose autologous cord blood to treat high risk cases or severe aplastic anaemia in the absence of an available sibling

donor. In another study<sup>14</sup> the outcome of HCT was similar for transplantation using RD, well matched URD, partial matched URD or UCB sources in patients with ALL. It was further stated that autologous HCT should no longer be used for high risk or relapsed ALL due to the unacceptably high relapse and poor long term survival. The study concluded that patients with ALL lacking a sibling donor can seek well matched UCB for best overall and LFS or well matched URD with a long term good chances of LFS.

### Genesis of UCB banks in the world

UCB has been shown to be a viable alternative to BM and PB. Further, UCB has clear advantages over the other sources of stem cells. It requires less restrictions for matching, as the naïve immune system appears to cause less severe GVHD. Perhaps most importantly, UCB is HLA typed and banked allowing for listing on a registry for rapid search and acquisition<sup>25</sup>.

Since the first successful transplant in a child with Fanconi anaemia in 1988, UCB has emerged as a feasible alternative source of haematopoietic progenitor/stem cells for allogenic transplantation<sup>26</sup>. To date, more than 10,000 patients worldwide have received an UCB transplant. Public UCB banks are growing in support of the increase in utilization of this newest graft source with recent reports indicating that there are greater than 450,000 unrelated units banked worldwide for potential clinical use<sup>13,27</sup>.

The first unrelated UCB bank was started at the New York Blood Center in 1992. There are now nearly 142 public banks and at least an additional 25 private banks actively involved around the world in collecting, processing, testing (*e.g.*, HLA typing, infectious disease testing), and cryopreserving UCB for potential future use as therapeutics<sup>13,28</sup> (Fig.). The highest inventory of 48,808 UCB is with New York Blood Center's National Cord Blood Program. This type of program in general is funded in part or entirely




Fig. Number of public UCB banks. (Source: Data obtained from Ref. 14).

by public funds. These banks are typically “not-for-profit” with their primary purpose being creation of an inventory of UCB units for unrelated use. UCB is donated to the bank, and the units are made available to suitably matched recipients regionally, nationally or internationally.

The alternative approach involves “for-profit” companies which encourage parents to bank their child’s UCB for their own (autologous) or a family member’s (related, allogeneic) use should a need arise. For a fee, the UCB is processed and stored as a form of “biological insurance”.

Most experts agree that public UCB banking is a sound idea<sup>29</sup> because of its accessibility to a vast number of people without any financial contribution for storage of UCB. This can potentially increase the storage of number of units that can meet the increasing demand world over with heterogeneous population of ethnic variation.

#### **Genesis of UCB banks in India and UCB banking organization in the Indian context**

With India’s booming birth rate of 26 million births per year<sup>30</sup> and genetic diversity; the country would be poised to be the largest collector of UCB in the world. Three public banks are established in India – Relicord, Jeevan Cord and Stemcyte, collectively having 5,000 units. Similarly, seven private banks have been established to date. These are Life Cell with maximum inventory of 19,000 followed by Cryo Banks having 17,000 plus samples and about 4,500 between Cryosave, Cord Life, Baby Cell, Stem One and ISSL (International Stem Cell Service) (personal communication from Dr Phagun Shah, Medical Advisor, Cryobank, India). Four of these are certified by ISO whereas Life cell and Relicord are accredited by AABB. Most of these are affiliated with or are subsidiaries of international companies.

The major problem faced in India is collection of UCB due to high cost and comparatively less functional public banks. In addition, considering a large population with deliveries in public hospital due to low cost, UCB storage in India needs increased public-private partnership model where UCB can be stored by affordable and non-affordable people as well.

#### **Progress of UCB banking for family use and its significance**

Families may choose to store UCB in a bank for prophylactic or pre-emptive reasons. When banked

preemptively, a family member is known to have or to be at increased risk for a potentially transplantable disease. In the promotional material, private UCB banks indicate that stored UCB may serve as a source of stem cell for autologous or allogenic haematopoietic stem cell transplantation and that these cells may be modified through gene transfer or targeted differentiation for treating degenerative disorders like Alzheimer disease, Parkinson disease and ischaemic heart disease<sup>28</sup>. In fact, at best in some cases, efficacy is speculative and may not even be under trial currently<sup>31</sup>. There are only a few reports that demonstrate the use of privately stored cord blood for autologous transplantation in leukemia and severe aplastic anaemia<sup>28</sup>. Expectant families may be vulnerable to this approach to marketing and may also rely heavily upon the opinion of the physician providing care. With emotional pressure, many parents decide to collect and store UCB despite estimates for future use in the range of 1:1000 to more than 1:200,000<sup>8,24,32</sup>.

Unlike private UCB banks, public banks are not aggressive with their marketing. Another important issue is access to the UCB stored in a public bank. After donation, the unit belongs to the bank; however, most banks will return a UCB unit to a family should it be needed and, of course, if it is still in the inventory at the time of request. In essence, a family donating a unit to a public bank does have a degree of a “biological insurance” as well. Alternatively, many private banks assure storage and accessibility for 15-20 yr. It appears that many Indian citizens opt for private UCB banking. The shelf-life or stability of UCB is uncertain<sup>8</sup> although there is evidence of efficacy in the range of 15-18 yr. There may be a degree of variance from unit to unit or bank to bank. Thus, it cannot be assumed that all units stored for a particular period of time will be equally potent and efficacious. More studies are necessary, and it is likely that each bank will need to establish stability within their own institution using their own units.

Expectant parents need to understand the true likelihood of their family benefiting from private UCB banking in order to make an informed decision about this expensive process. Parents need to be aware that the success rates described for UCB relate to haematological disorders within the family (usually sibling donations), and the usefulness of autologous or related UCB in other disorders is still under trial.

#### **Regulatory environment in India and other countries**

At present, the role that any government should play in UCB banking remains unclear. However, in

developed and developing countries with a universally accessible healthcare system, public policy makers will soon be confronted with the difficult task of deliberating the merits and economics of establishing a national network of public UCB banks, including the value of private banking of UCB for autologous/family use. A policy framework may be necessary to guide this decision-making.

The Guidelines from the Indian Council of Medical Research (ICMR) and Department of Biotechnology (DBT) are available to assist with stem cell research and UCB issues<sup>33</sup>. Additionally, the aforementioned standards (AABB, FACT/NETCORD) could facilitate the effort to establish public UCB banks throughout India. Roughly 0.25 per cent of the global shares of UCB transplants are done in India, and only three ICMR licensed UCB banks are operational in the country<sup>22,34</sup>. The field of UCB stem cell therapy is still gaining experience in India, and there are many regulatory and policy issues pertaining to the allogeneic transplantation for inherited disorders and transmissible infectious diseases that are yet to be addressed in addition to the draft guidelines by ICMR and DBT. There are unique ethical issues related to private UCB banking, and policymakers cannot chart the future of UCB banking in the country without taking into account the existence of private banks and their potential role in meeting future clinical needs, as well as their actual and potential contribution to research in this domain. Now is the time to prospectively address the socio-ethical and legal issues surrounding UCB banking and uses.

The Canadian Standards Association has published standards which are applicable to UCB banking for transplantation – Cells, Tissues, and Organs for Transplantation and Assisted Reproduction: General Requirements and Lymphohematopoietic Cells for Transplantation<sup>32</sup>. The standards set by accreditation bodies also help to promote the safety of UCB banking practices, although the accreditation process remains voluntary and, therefore, cannot be relied upon to protect the public interest with regard to UCB-based therapeutics.

Several organizations have taken the position that UCB banking for autologous use should be discouraged. The Society of Obstetricians and Gynecologists of Canada Clinical Practice Guidelines<sup>32</sup> and American Academy of Pediatrics<sup>8</sup> clearly state that collection and long-term storage of UCB for autologous donation is not recommended because of the limited indications

and lack of scientific evidence to support the practice. The clinical utility of autologous UCB storage is said to be limited because of the very low probability that an autologous haematopoietic stem cell transplant will be required by the individual in his/her lifetime, the uncertain shelf-life of stored UCB, and the fact that autologous transplants are not recommended for inherited disorders or blood cancers<sup>12</sup>. UCB education is also supported by legislation at the federal and State levels in USA. The Institute of Medicine (IoM) report “Establishing a National Cord Blood Stem Cell Bank Program” recommends that expectant parents be given a balanced perspective on their options for cord blood banking for donating, discarding or banking life saving newborn stem cells<sup>35</sup>. The National Marrow Donor Program estimates that by the year 2015, there will be 10,000 UCBT worldwide per year using publically banked cord blood. Therefore, it is vitally important to build public repositories of cord blood donations throughout the world<sup>13</sup>.

The European Union Group on Ethics (EGE) has issued opinion No. 19 titled Ethical Aspects of Umbilical Cord Blood Banking that the legitimacy of commercial UCB banks for autologous use should be questioned as they sell a service which has presently no real use regarding therapeutic options. However, in the final section 1.27, the EGE admits that if the future regenerative medicine developed using autologous stem cell then the fact to have one’s own cord blood being stored at birth could increase the chance of having access to new therapies<sup>36</sup>. It is hoped that autologous UCB stem cells will prove to be of particular value for cellular therapy and regenerative medicine, but, again, at present many uses remain speculative.

### **Possible applications of UCB for regenerative medicine application**

Regenerative medicine is a field of medical research developing treatments to repair or re-grow specific tissue in the body. UCB cells are an attractive choice for tissue engineering and regenerative medicine, as these have shown promise for numerous disease states. The identification of one cell type in UCB, mesenchymal stem cells (MSCs), heralds UCB as an untapped resource for non-haematopoietic stem cell-based therapeutic strategies for the replacement of injured or diseased connective tissue<sup>37</sup>. UCB-derived endothelial progenitor cells (EPCs) are another logical cell type for use in tissue engineering and regenerative medicine. Janic *et al*<sup>38</sup> demonstrated that UCB-derived AC133+ cells were primarily EPCs capable of maintenance of

endothelial lineage in long-term culture. A recent study by Li *et al*<sup>39</sup> successfully used micro-encapsulated UCB cells for liver injury in mice. This represents a future possible alternative to liver transplantation. The use of UCB stem cells in treating brain injury and type I diabetes is already being studied in humans and earlier stage of research is being conducted for stroke and hearing loss<sup>40-43</sup>.

The potential for the use of UCB stem cells to regenerate insulin production in juvenile diabetes patients has been reported<sup>38</sup>. These children are now pioneers in helping to develop effective therapies for juvenile diabetes using one's own stem cells. This option is only available to those whose parents made the decision to preserve their UCB<sup>41</sup>.

In a meeting of the International Society for Stem Cell Research in 2007, the potential for UCB stem cells to improve outcomes in human patients following heart attack was presented by Dr Harris. The data showed that in an animal model of heart attack, intracoronary delivery of cord blood stem cells increased the vascular density in the heart compared to untreated animals<sup>44</sup>.

Research in animal models have shown that UCB stem cells injected intravenously have the ability to migrate to the area of brain injury alleviating mobility related symptoms. Further, injecting human UCB stem cells into animals with stroke was shown to significantly improve behaviour by stimulating the new blood vessels formation and neurons in the brain<sup>45</sup>. Vision loss can occur when corneal epithelial cells are lost or are not replaced quickly. Scientists have demonstrated that UCB stem cells can differentiate into the cells that are indistinguishable from corneal epithelial cells. When transplanted in animals, UCB stem cells improved the appearance of the corneal surface suggesting that UCB could provide a future therapeutic option for ocular surface disorder<sup>46</sup>.

All these studies indicate that children whose UCB stem cells are available for their own potential use could be among the first one to benefit from the newer research in UCB transplantation without having the risk of rejection by the immune system.

### **Novel approaches of UCB transplantation**

For older patients and those with co-morbidities in addition to malignancy and extensive pre-transplant treatment, reduced intensity conditioning transplants reduced intensity conditioning (RIC) may achieve the same goals as with myeloablative conditioning but

with less toxicity. Brunstein *et al*<sup>47</sup> reported results in 110 adults transplanted with UCB for haematological diseases with 92 per cent sustained engraftment, 19 per cent TRM and three year overall survival (OS) of 45 per cent which is similar to those with other stem cell sources. This study thus extends the availability of transplantation therapy to the elderly excluded on the basis of age and lack of a suitable matched donor and those with co-morbid conditions.

### **Expansion of UCB stem cells**

UCB can be expanded *ex vivo* over 400-fold by culture techniques that can block cell differentiation with elimination of certain components like copper. Peled *et al*<sup>48</sup> indicate that 3 wk treatment with a copper chelator results in preferential proliferation of a subset of CD34+ cells which seem to be responsible for expansion in long term culture. Recently Deutsch *et al*<sup>49</sup> demonstrated a novel approach to UCB stem and progenitor cell expansion through haematopoietic niche mimicry using fibronectin and acetylcholine esterase read-through peptide (ARP). The work by Delaney *et al*<sup>50</sup> is most promising as it is the first example of rapid engraftment of *ex vivo* expanded UCB in humans with a median time to neutrophil engraftment of 16 days (range 7-34). This study is now moving to phase II (efficacy) trials in the USA, and the results are highly anticipated. Several additional studies involving unique approaches to UCB expansion are underway in the research laboratories and early clinical trials setting<sup>38,51-53</sup>.

### **Double unit transfusion**

Simultaneous transfusion of two UCB units obtained from different donors of HLA mismatched UCB units showed lower time of engraftment (12-28 days) than the median duration using single UCB unit without influencing GVHD<sup>54</sup>. In phase I clinical trial of 23 adults with high risk haematologic malignancies, double unit UCB transplant with 1-2 HLA mismatch and total TNC dose of  $3.6 \times 10^7/\text{kg}$  with CD34+ dose of  $3.7 \times 10^5/\text{kg}$ , led to neutrophil recovery at 24 days (median) for myeloablative conditioning and 13.5 days (median) for non-myeloablative conditioning. The overall survival in this high risk patient was 33 per cent at one year. The causes of death were graft failure, GVHD or progressive disease and infection/regimen related toxicity. This observation clearly suggests that two different UCB units are not associated with crossed immunological rejection and suggests that immunological mechanisms may

facilitate engraftment in donors receiving two unrelated UCB units.

### Co-infusion of other cell types

Acute GVHD occurs after allogeneic haematopoietic stem cell transplantation resulting from the donor immune cells against host tissues. About 35 to 50 per cent of HSCT recipients develop acute GVHD with considerable morbidity and mortality. In such instances naturally occurring CD25+, CD4+ suppressor, or Treg cells, and mesenchymal stem cells (MSCs) have been shown to mediate immunomodulating effects. Godfrey *et al*<sup>55</sup> have demonstrated UCB as a superior source for Treg cell isolation and expansion compared with adult peripheral blood. UCB contains a significant number of Treg cells capable of potent suppressive function after culture, and banked UCB specimens may serve as a readily available source of Treg cells for immunotherapy. Trials are ongoing at the University of Minnesota and early results are promising<sup>56</sup>.

Mesenchymal stem/stromal cells have also been shown to mediate immunomodulatory effects in the research laboratories, and this has set the stage for their clinical testing for this effect<sup>57</sup>. MSCs appear to exert their immunomodulatory effects by secreting various cytokines and growth factors. Trials of marrow-derived MSCs are underway for autoimmune disorders like Crohn's disease and type I diabetes. There is a great promise for MSCs in general, though less is known of UCB-derived MSCs.

Additionally, MSCs have been shown to provide haematopoietic engraftment support through angiogenic and neurogenic mechanisms. This has led to the intriguing possibility that co-infusion of MSCs and haematopoietic cells can shorten the time to engraftment and reduce graft failure after transplant though with less clear evidence whether MSCs are equally supportive of UCB transplants<sup>58</sup>.

### Conclusion

India has great potential for UCB banking due to a high birth rate and genetic diversity. Nearly 70 per cent of patients of Indian origin who require bone marrow transplantation do not find a match within their own family. Hence, unrelated UCB is a widely accepted source of progenitors for haematopoietic stem cell transplantation. However, to-date the total number of UCB transplants performed in India has been very low mainly due to high cost and limited number of

UCB units available against the estimated requirement of 30,000 units. But with the existence of three public UCB banks these figures are likely to improve in the coming years. This will offer a diverse source of high quality grafts for patients of Indian origin worldwide. Private banks continue to grow in India, as many families opt to store UCB in private banks with possible advantages in degenerative disorders in the future. To meet the future transplantation needs of the country, full participation and substantial investment by the Government is necessary. Establishing a foundation, including infrastructure (facilities, technical and quality assurance expertise, *etc.*) will support an UCB programme which will be representative for all regions of the country.

### Acknowledgment

Authors acknowledge the UICC-ICRETT fellowship awarded to the second author (JS) to undergo training at University of Minnesota, USA and thank Dr Frenny Sheth for valuable suggestions in manuscript preparation, Dr Revathi Raj of Apollo Hospital, Chennai and Dr Sandip Shah of GCRI, Ahmedabad, for providing important information of UCB transplantation in India.

### References

1. Cohen Y, Nagler A. Umbilical cord blood transplantation – how, when and for whom? *Blood Rev* 2004; 18 : 167-79.
2. Martin PL, Carter SL, Kernan NA, Sahdev I, Wall D, Pietryga D, *et al*. Results of the cord blood transplantation study (COBLT): outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with lysosomal and peroxisomal storage diseases. *Biol Blood Marrow Transplant* 2006; 12 : 184-94.
3. Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A, *et al*. Transplants of umbilical cord blood or bone marrow from unrelated donors in adults with acute leukemia. *N Engl J Med* 2004; 351 : 2276-85.
4. Bensinger WI, Clift R, Martin P, Appelbaum FR, Demirew T, Gooley T, *et al*. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. *Blood* 1996; 88 : 2794-800.
5. Cohen Y, Nagler A. cord blood biology & transplantation. *Isr Med Assoc J* 2004; 6 : 39-46.
6. Cohen Y, Nagler A. Hematopoietic stem-cell transplantation using umbilical cord blood. *Leuk Lymphoma* 2003; 44 : 1287-99.
7. Lusin BH, Shearer WT. American Academy of Pediatrics section on Hematology/Oncology; American Academy of Pediatrics section on Allergy/immunology. Cord blood banking for potential future transplantation. *Pediatrics* 2007; 119 : 165-70.
8. McCullough J, McKenna D, Kadidlo D, Schierman T, Wagner J. Issues in the quality of umbilical cord blood stem cells for transplantation. *Transfusion* 2005; 45 : 832-41.

9. American Association of Blood Banks. *Standards for cellular therapy product services*, 2<sup>nd</sup> ed. Bethesda MD: American Association of Blood Banks; 2007.
10. Net Cord Foundation for the Accreditation of Cellular Therapy. *International standards for cord blood collection, processing, testing, banking, selection and release*. 3<sup>rd</sup> ed. Bethesda, MD: American Association of Blood Banks; 2006.
11. Steinbrook R. The cord-blood bank controversies. *N Engl J Med* 2004; *351* : 2255-7.
12. World Marrow Donor Association. *Stem cell registries annual report*, 10<sup>th</sup> ed. Leiden: World Marrow Donor Association; 2007.
13. [http://www.worldmarrow.org/fileadmin/WorkingGroups\\_Subcommittees/Cord\\_Blood\\_Working\\_Group/Cord\\_Blood\\_Banks\\_Worldwide\\_13042010.pdf](http://www.worldmarrow.org/fileadmin/WorkingGroups_Subcommittees/Cord_Blood_Working_Group/Cord_Blood_Banks_Worldwide_13042010.pdf), accessed on September 12, 2010.
14. Tomblyn MB, Arora M, Baker KS, Blazar BR, Brunstein CG, Burns LJ, *et al*. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome. *J Clin Oncol* 2009; *27* : 3634-41.
15. Ponce D, Zheng J, Gonzales AM, Castro-Malaspina HR, Hsu KC, Jakubowski A, *et al*. Disease-free survival after cord blood (CB) transplantation is not different to that after related or unrelated donor transplantation in patients with hematologic malignancies. *51<sup>st</sup> ASH Annual Meeting and Exposition - On Line Programme and Abstracts*. 2009; Abstract no. 2296.
16. Gutman JA, Leisenring W, Appelbaum FR, Woolfrey AE, Delaney C. Low relapse without excessive transplant-related mortality following myeloablative cord blood transplantation for acute leukemia in complete remission: a matched cohort analysis. *Biol Blood Marrow Transplant* 2009; *15* : 1122-9.
17. Harris DT. Non-haematological user of cord blood stem cells. *Br J Haematol* 2009; *147* : 177-84.
18. Locatelli F, Rocha V, Reed W, Bernaudin F, Ertem M, Grafakos S, *et al*. Eurocord Transplant Group. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. *Blood* 2003; *101* : 2137-43.
19. Jaing TH, Hung IJ, Yang CP, Tsai MH, Lee WI, Sun CF. Second transplant with two unrelated cord blood units for early graft failure after cord blood transplantation for thalassemia. *Pediatr Transplant* 2009; *13* : 766-8.
20. Gluckman E, Rocha V, Ionescu I, Bierings M, Harris R, Wagner J, *et al*. Results of unrelated cord blood transplant in Fanconi Anemia patients: Risk factor analysis for engraftment and survival. *Biol Blood Marrow Transplant* 2007; *13* : 1073-82.
21. Prasad VK, Mendizabal A, Parikh SH, Szabolcs P, Driscoll TA, Page K, *et al*. Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular composition of the graft on transplantation outcomes. *Blood*. 2008; *112* : 2979-89.
22. Umbilical cordblood. Available from: <http://parents.guidecordblood.org/content/usa/banklists/summary.shtml#india> last modified on 13<sup>th</sup> Sept. 2010 accessed on September 14, 2010.
23. Barker JN. Umbilical Cord Blood (UCB) transplantation: an alternative to the use of unrelated volunteer donors? *Hematology Am Soc Hematol Educ Program* 2007; 55-61.
24. Thornley I, Eapen M, Sung L, Lee SJ, Davies SM, Joffe S. Private cord blood banking: Experiences and views of pediatric hematopoietic cell transplantation physicians. *Pediatrics* 2009; *123* : 1011-7.
25. Barker JN, Krepski TP, DeFor TE, Davies SM, Wagner JE, Weisdorf DJ. Searching for unrelated donor hematopoietic stem cells: availability and speed of umbilical cord blood versus bone marrow. *Biol Blood Marrow Transplant* 2002; *8* : 257-60.
26. Gluckman E, Broxmeyer HA, Auerbach AD, Friedman HS, Douglas GW, Devergie A, *et al*. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from HLA-identical sibling. *N Engl J Med* 1989; *321* : 1174-8.
27. Sacchi N, Costeas P, Hartwell L, Hurley CK, Raffoux C, Rosenmayr A, *et al*; Quality Assurance and Clinical Working Groups of the World Marrow Donor Association. Hematopoietic stem cell donor registries: World Marrow Donor Association recommendations for evaluation of donor health. *Bone Marrow Transplant* 2008; *42* : 9-14.
28. Cord blood Registry. Why you should save cord blood for your family. Available from: [http://www.cordblood.com/cord\\_blood\\_banking\\_with\\_cbr/banking/diseases\\_treated.asp?fbid=BlyS\\_OAIG4n](http://www.cordblood.com/cord_blood_banking_with_cbr/banking/diseases_treated.asp?fbid=BlyS_OAIG4n), accessed on April 13, 2010.
29. [No authors listed]. Private cord blood banks. *Med Lett Drugs Ther* 2004; *46* : 21-2.
30. <http://www.savethechildren.in/87-news-releases/130-child-mortality-in-india.html>, accessed on August 18, 2011.
31. Viacord. Using stem cells to potentially treat heart disease. Available from: [www.viacord.com/stem-cells-heart-disease.htm](http://www.viacord.com/stem-cells-heart-disease.htm), accessed on September 14, 2010.
32. Armson BA; Maternal Fetal Medicine Committee, Society of Obstetricians and Gynecologists of Canada. Umbilical cord blood banking: implications for perinatal care providers. *J Obstet Gynaecol Can* 2005; *27* : 263-90.
33. ICMR-DBT guidelines for stem cell Research & Therapy. 2006; <http://medind.nic.in/iby/t06/i9/ibyt06i9p371.pdf>, accessed on September 14, 2010.
34. <http://www.parentsguidecordblood.org/content/usa/banklists/regulations.shtml?navid=31#india> last updated. April 23 2010, accessed on September 14, 2010.
35. [http://www.iom.edu/en/Activities/Research/Cordblood\\_Bank.aspx](http://www.iom.edu/en/Activities/Research/Cordblood_Bank.aspx), accessed on November 22, 2010.
36. Opinion No 19. [http://ec.europa.eu/european\\_group\\_ethics/docs/avis19\\_en.pdf](http://ec.europa.eu/european_group_ethics/docs/avis19_en.pdf), European Union group on ethics, accessed on November 22, 2010.
37. Cetrulo CL. Cord-blood mesenchymal stem cells and tissue engineering. *Stem Cell Rev* 2006; *2* : 163-8.
38. Janic B, Guo AM, Iskander AS, Varma NR, Scicli AG, Arbab AS. Human cord blood derived AC133+ progenitor cells preserve endothelial progenitor characteristics after long term *in vitro* expansion. *PLoS ONE* 2010; *5* : e9173.
39. Li S, Sun Z, Lv G, Guo X, Zhang Y, Yu W, *et al*. Microencapsulated UCB cells repair hepatic injure by



- intraperitoneal transplantation. *Cytotherapy* 2009; 11 : 1032-40.
40. Cord Blood for Neonatal Hypoxic-Ischemic Encephalopathy, Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy Study 1. Phase I Study of Feasibility and Safety <http://clinicaltrials.gov/ct2/show/NCT00593242>, accessed on August 18, 2011.
  41. Haller MJ, Viener HL, Wasserfall C, Brusko T, Atkinson MA, Schatz DA. Autologous umbilical cord blood infusion for type 1 diabetes. *Exp Hematol* 2008; 36 : 710-5.
  42. Vendrame M, Gemma C, Pennypacker KR, Bickford PC, Sanberg DC, Sanberg PR, *et al.* Cord blood rescues stroke-induced changes in splenocyte phenotype and function. *Exp Neurol* 2006; 199 : 191-200.
  43. Vendrame M, Gemma C, de Mesquita D, Collier L, Bickford PC, Sanberg CD, *et al.* Anti-inflammatory effects of human cord blood cells in a rat model of stroke. *Stem Cells Dev* 2005; 14 : 595-604.
  44. Harris DT, He H, Gaballa M. The potential of cord blood stem cells for use in regenerative medicine of the heart. *2nd International Stem Cells Meeting, San Francisco, CA, 22-24 January 2007.*
  45. Taguchi A, Soma T, Tanaka H, Kanda T, Nishimura H, Yoshikawa H, *et al.* Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. *J Clin Invest* 2004; 114 : 330-8.
  46. Harris DT, He X, Badowski M, Nicols JC. Regenerative Medicine of the eye: a Short review. In: Levicar N, Habib NA, Dimarakis I, Gordon MY, editors. *Stem cell repair & regeneration*, vol. 3. London: Imperial College Press; 2008. p. 211-25.
  47. Brunstein CG, Setubal DC, Wagner JE. Expanding the role of umbilical cord blood transplantation. *Br J Haematol* 2007; 137 : 20-35.
  48. Peled T, Mandel J, Goudsmid RN, Landor C, Hasson N, Harati D, *et al.* Pre-clinical development of cord blood-derived progenitor cell graft expanded *ex vivo* with cytokines and the polyamine copper chelator tetraethylenepentamine. *Cytotherapy* 2004; 6 : 344-55.
  49. Deutsch V, Hubel E, Kay S, Ohayon T, Katz BZ, Many A, *et al.* Mimicking the haematopoietic niche microenvironment provides a novel strategy for expansion of haematopoietic and megakaryocyte-progenitor cells from cord blood. *Br J Haematol* 2010; 149 : 137-49.
  50. Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, Bernstein ID. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. *Nat Med* 2010; 16 : 232-6.
  51. McKenna DH, Kadidlo DM, Miller JS, Orchard PJ, Wagner JE, McCullough J. The Minnesota Molecular and Cellular Therapeutic Facility: a state of the art biotherapeutics engineering laboratory. *Transfus Med Rev* 2005; 19 : 217-28.
  52. Madlambayan GJ, Rogers I, Purpura KA, Ito C, Yu M, Kirouac D, *et al.* Clinically relevant expansion of hematopoietic stem cells with conserved function in a single use, closed system bioprocess. *Biol Blood Marrow Transplant* 2006; 12 : 1020-30.
  53. Delaney C, Heimfeld S, Basdhem-Stein C, Voorhies H, Manger RL, Bernstein ID. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. *Nat Med* 2010; 16 : 232-6.
  54. Jaing TH, Yang CP, Hung IJ, Chen SH, Sun CF, Chow R. Transplantation of unrelated donor umbilical cord blood utilizing double-unit grafts for five teenagers with transfusion dependant Thalassemia. *Bone Marrow Transplant* 2007; 40 : 307-11.
  55. Godfrey WR, Ge YG, Spoden DJ, Levine BL, June CH, Blazar BR, *et al.* *In vitro*-expanded human CD4(+) CD25(+) T-regulatory cells can markedly inhibit allogenic dendritic cell-stimulated MLR cultures. *Blood* 2004; 104 : 453-61.
  56. Brunstein CG, Hippen K, McKenna DH, Cao Q, Miller JS, Blazar BR, *et al.* *Ex vivo* expanded umbilical cord blood (UCB)-derived regulatory cells to recipients of non-myeloablative unrelated double UCB transplantation. *Blood (ASHG American Society of Hematology Annual meeting abstracts)* 2009; 114 : Abstract no. 513.
  57. Tolar J, Hippen KL, Blazar BR. Immune regulatory cells in umbilical cord blood: T regulatory cells and mesenchymal stromal cells. *Br J Haematol* 2009; 147 : 200-6.
  58. Ball LM, Bernardo ME, Roelofs H, Lankester A, Cometa A, Egeler RM, *et al.* Cotransplantation of *ex vivo* expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. *Blood* 2007; 110 : 2764-7.

Reprint requests: Dr Jayesh Sheth, Foundation for Research in Genetics & Endocrinology, "FRIGE House",  
Jodhpur Gam Road, Satellite, Ahmedabad 380 015, India  
e-mail: jshethad1@gmail.com